EP4352056A1 — Solid state forms of lanifibranor and process for preparation thereof
Assigned to Assia Chemical Industries Ltd · Expires 2024-04-17 · 2y expired
What this patent protects
The present disclosure encompasses solid state forms of Lanifibranor, in embodiments crystalline polymorphs of Lanifibranor, processes for preparation thereof, and pharmaceutical compositions thereof.
USPTO Abstract
The present disclosure encompasses solid state forms of Lanifibranor, in embodiments crystalline polymorphs of Lanifibranor, processes for preparation thereof, and pharmaceutical compositions thereof.
Drugs covered by this patent
- Tygacil (TIGECYCLINE) · Fresenius Kabi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.